Across TCGA pan-cancer cohorts, CD300LD Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CD300LD data layer compared with 20 for mass-spec protein.
The strongest signal is observed in thymoma (THYM), where higher CD300LD Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CD300LD expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.
THYM, LUAD, and BLCA are the cancer types where CD300LD Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.